Drug intelligence / Profile preview

momelotinib + trametinib

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **momelotinib**, a Janus kinase (JAK) and TANK-binding kinase 1 (TBK1) inhibitor, and **trametinib**, a mitogen-activated protein kinase kinase (MEK) inhibitor. Momelotinib is primarily used in treating myelofibrosis, while trametinib is used in cancers with BRAF mutations. The combination has been explored for treating KRAS-mutated non-small cell lung cancer (NSCLC).

Targets

JAK2 (Janus kinase 2)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)TBK1 (TANK binding kinase 1)JAK1 (Janus kinase 1)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on momelotinib + trametinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on momelotinib + trametinib.

Explore the full profile